Peraso (PRSO) 10-K 18 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 12, 2021	Jun. 30, 2020
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Registrant Name	MOSYS, INC.
Entity Central Index Key	0000890394
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-32929
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0291941
Entity Address, Address Line One	2309 Bering Drive
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95131
City Area Code	408
Local Phone Number	418-7500
Document Annual Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		6,133,719
Entity Public Float			$ 6,427,310
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Undesignated Common Stock
Trading Symbol	MOSY
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Series AA Preferred Stock
Title of 12(b) Security	Series AA Preferred Stock, par value $0.01 per share
No Trading Symbol Flag	true

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 5,889	$ 6,053
Short-term investments		300
Accounts receivable, net	701	1,175
Inventories	599	968
Prepaid expenses and other	668	472
Total current assets	7,857	8,968
Property and equipment, net	121	197
Right-of-use lease asset	303	156
Other	17	78
Total assets	8,298	9,399
Current liabilities
Accounts payable	76	218
Deferred revenue	15	166
Short-term lease liability	201	166
PPP note payable, current	244
Accrued expenses and other	1,300	1,155
Total current liabilities	1,836	1,705
Long-term lease liability	103
PPP note payable	335
Convertible notes payable	3,092	2,858
Total liabilities	5,366	4,563
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 120,000 shares authorized; 3,554 shares and 2,179 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	3	2
Additional paid-in capital	245,548	243,281
Accumulated deficit	(242,619)	(238,447)
Total stockholders’ equity	2,932	4,836
Total liabilities and stockholders’ equity	$ 8,298	$ 9,399

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	3,554,000	2,179,000
Common stock, shares outstanding	3,554,000	2,179,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net revenue
Total net revenue	$ 6,795,000	$ 10,086,000
Cost of net revenue	2,329,000	3,931,000
Gross profit	4,466,000	6,155,000
Operating expenses
Research and development	3,989,000	4,182,000
Selling, general and administrative	4,028,000	4,016,000
Impairment of goodwill		420,000
Total operating expenses	8,017,000	8,618,000
Loss from operations	(3,551,000)	(2,463,000)
Interest expense	(243,000)	(220,000)
Other income, net	14,000	103,000
Net loss	(3,780,000)	(2,580,000)
Deemed dividend for warrant exercise price adjustment	(392,000)
Net loss attributable to common stockholders	$ (4,172,000)	$ (2,580,000)
Net loss per share attributable to common stockholders
Basic and diluted	$ (1.32)	$ (1.19)
Shares used in computing net loss per share
Basic and diluted	3,167	2,165
Product
Net revenue
Total net revenue	$ 5,933,000	$ 9,377,000
Royalty and Other
Net revenue
Total net revenue	$ 862,000	$ 709,000

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2018	$ 7,157,000	$ 2,000	$ 243,022,000	$ (235,867,000)
Beginning Balance, shares at Dec. 31, 2018		2,148
Issuance of common stock under stock plans, net	(4,000)		(4,000)
Issuance of common stock under stock plans, net, shares		31
Stock-based compensation	263,000		263,000
Net loss	(2,580,000)			(2,580,000)
Ending Balance at Dec. 31, 2019	$ 4,836,000	$ 2,000	243,281,000	(238,447,000)
Ending Balance, shares at Dec. 31, 2019	2,179	2,179
Issuance of common stock under stock plans, net	$ (2,000)		(2,000)
Issuance of common stock under stock plans, net, shares		41
Exercise of pre-funded warrants	2,000		2,000
Exercise of pre-funded warrants, shares		116
Sale of common stock, net of financing	1,619,000	$ 1,000	1,618,000
Sale of common stock, net of financing, shares		1,218
Deemed dividend for warrant exercise price adjustment	392,000		392,000	(392,000)
Stock-based compensation	257,000		257,000
Net loss	(3,780,000)			(3,780,000)
Ending Balance at Dec. 31, 2020	$ 2,932,000	$ 3,000	$ 245,548,000	$ (242,619,000)
Ending Balance, shares at Dec. 31, 2020	3,554	3,554

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (3,780)	$ (2,580)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Provision for doubtful accounts	41
Depreciation and amortization	143	185
Stock-based compensation	257	263
Impairment of goodwill		420
Accrued interest	243	220
Loss on disposal of assets	4
Amortization of lease right-of-use asset	212	212
Change in operating lease liability	(220)	(219)
Other	(1)	(6)
Changes in assets and liabilities
Accounts receivable	433	447
Inventories	369	180
Prepaid expenses and other assets	(135)	416
Accounts payable	(142)	(18)
Deferred revenue and other liabilities	(15)	(171)
Net cash used in operating activities	(2,591)	(651)
Cash flows from investing activities:
Purchases of property and equipment	(71)	(103)
Proceeds from maturities of marketable securities and investments	300	1,275
Purchases of marketable securities and investments		(1,568)
Net cash provided by (used in) investing activities	229	(396)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants, net of issuance costs	1,619
Net proceeds from exercise of pre-funded warrants	2
Taxes paid to net share settle equity awards	(2)	(4)
Net cash provided by (used in) financing activities	2,198	(4)
Net decrease in cash and cash equivalents	(164)	(1,051)
Cash and cash equivalents at beginning of year	6,053	7,104
Cash and cash equivalents at end of year	5,889	6,053
Supplemental disclosure:
Cash paid for income taxes	2	2
Noncash investing and financing activities:
Issuance of convertible notes in settlement of accrued interest	234	$ 187
Fair value of warrant exercise price adjustment considered as deemed dividend	392
PPP Note
Cash flows from financing activities:
Proceeds from PPP note	$ 579

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	Note 1: The Company and Summary of Significant Accounting Policies The Company MoSys, Inc. (the Company) was incorporated in California in 1991 and reincorporated in 2000 in Delaware. The Company provides both integrated circuits (ICs) and intellectual property (IP) solutions that enable fast, intelligent data access and decision making for a wide range of markets. The Company’s primary product line is marketed under the Accelerator Engine name and includes the Bandwidth Engine IC products, which integrate the Company’s proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. Virtual Accelerator Engine products which consist of software, firmware and related IP. This new product line will include multiple function accelerator platform products, which target specific application functions and will use a common software interface to allow performance scalability over multiple hardware environments. Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted. In March 2020, Santa Clara County in California, where the Company is based, issued a ”shelter-in-place” order (the Order) that was initially effective through April 7, 2020 and has now been extended. The Company has been complying with the Order and have minimized business activities at the San Jose headquarters facility (the only facility). The Company has implemented a teleworking policy for employees and contractors to reduce on-site activity at the facility. The Order impacted the Company’s ability to produce and ship IC products in the second half of March 2020, as certain vendors in the San Francisco Bay Area closed in accordance with the Order. In April 2020, the Company resumed shipments of IC products, as they are supporting shipment of components for critical infrastructure, as defined by the federal government; however, employees are generally restricted from visiting customer and vendor sites in compliance with the Order, and, in some cases, have limited ability to conduct certain product testing and development activities. The Company remains diligent in continuing to identify and manage risks to our business given the changing uncertainties related to COVID-19. The ultimate impact of the Covid-19 pandemic on the business and results of operations is uncertain and difficult to predict, and the Company is closely monitoring impacts, especially to customer programs and our supply chain. The Company expects that the impacts of the COVID-19 pandemic will have a negative impact on its revenues for 2021, although the Company is not in a position to quantify such impacts. In addition, the Company has and continues to experience longer lead times for certain components used to manufacture its IC products. While the Company believes that operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, they recognize that unpredictable events could create difficulties in the months ahead. The Company may not be able to address these difficulties in a timely manner, which could negatively impact its business, results of operations, financial condition and cash flows. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Material estimates may include assumptions made in determining reserves for uncollectible receivables, inventory write-downs, impairment of long-term assets, valuation allowance on deferred tax assets, accruals for potential liabilities and assumptions made in valuing equity instruments. Cash Equivalents and Investments The Company has invested its excess cash in money market accounts, certificates of deposit, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term and long-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income (loss). Realized gains and losses and declines in the value judged to be other-than-temporary are included in the other income, net line item in the consolidated statements of operations. The cost of securities sold is based on the specific identification method. Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2—Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities include cash equivalents and available-for-sale securities, which consisted primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3—Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts receivable was $41,000 and zero as of December 31, 2020 and 2019, respectively. Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow-moving inventory items. The Company recorded inventory write-downs of $0.1 million for each of the years ended December 31, 2020 and 2019. Property and Equipment Property and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in cost of sales and operating expenses in the consolidated statements of operations and comprehensive loss. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Valuation of Long-lived Assets The Company evaluates the recoverability of long-lived assets with finite lives whenever events or changes in circumstances occur that indicate that the carrying value of the asset or asset group may not be recoverable. Finite-lived intangible assets are being amortized on a straight-line basis over their estimated useful lives of three to seven years. An impairment charge is recognized as the difference between the net book value of such assets and the fair value of such assets at the date of measurement. The measurement of impairment requires management to estimate future cash flows and the fair value of long-lived assets. Goodwill The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired. If the carrying value of the reporting unit’s goodwill exceeds its fair value, then the Company must record an impairment charge equal to the difference. The Company performed its annual test for goodwill impairment as of September 1, 2019, and, due to a decrease in the price per share of its common stock, the test results indicated the goodwill carrying value was greater than its implied fair value. Further, the Company concluded a triggering event had occurred due to the sustained decrease in the price per share of its common stock and related reduced market capitalization as of September 30, 2019 and performed an additional test for impairment of its goodwill asset resulting in further indication that the goodwill carrying value was still greater than its implied fair value. As a result of both of these tests, the Company recorded non-cash impairment charges totaling $0.4 million. As a result of these charges, the Company’s goodwill balance was reduced to zero at September 30, 2019. Revenue Recognition The Company recognizes revenue in accordance with Financial Accounting Standards Board ( Revenue from Contracts with Customers, As described below, the analysis of contracts under ASC 606 supports the recognition of revenue at a point in time, resulting in revenue recognition timing that is materially consistent with the Company’s historical practice of recognizing product revenue when title and risk of loss pass to the customer. The Company generates revenue primarily from sales of IC products and licensing of its intellectual property. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company's contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less. The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. As of December 31, 2020, contract liabilities were in a current position and included in deferred revenue. During the year ended December 31, 2020, the Company recognized revenue of $0.2 million that had been included in deferred revenue as of December 31, 2019. During the year ended December 31, 2019, the Company recognized revenue of $0.3 million that had been included in deferred revenue as of December 31, 2018. See Note 8 for disaggregation of revenue by geography. The Company does not have significant financing components, as payments from customers are typically due within 60 days of invoicing, and the Company has elected the practical expedient to net value financing components that are less than one year. Shipping and handling costs are generally incurred by the customer, and, therefore, are not recorded as revenue. Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products. Advertising Costs Advertising costs are expensed as incurred. Advertising costs were not significant for the years ended December 31, 2020 and 2019. Research and Development Engineering costs are recorded as research and development expense in the period incurred. Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees. The Company accounts for such grants based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the vesting period. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods. Per Share Amounts Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and purchases under the employee stock purchase plan, conversion of convertible debt and exercise of warrants. The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): December 31, 2020 2019 Options to purchase common stock 159 161 Unvested restricted common stock units 65 103 Convertible debt 271 254 Warrants 1,879 1,994 Total 2,374 2,512 Income Taxes The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. The 2014 through 2018 tax years generally remain subject to examination by U.S. federal and state tax authorities, and the 2010 through 2019 tax years generally remain subject to examination by foreign tax authorities. At December 31, 2020, the Company did not have any material unrecognized tax benefits nor expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest related to unrecognized tax benefits as income tax expense and penalties related to unrecognized tax benefits as other income and expense. During the years ended December 31, 2020 and 2019, the Company did not recognize any interest or penalties related to unrecognized tax benefits. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2020 and 2019, the Company’s comprehensive loss was the same as its net loss.

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	12 Months Ended
	Dec. 31, 2020
Consolidated Balance Sheets And Statements Of Operations Components Disclosure [Abstract]
Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss Components	Note 2: Consolidated Balance Sheet Detail December 31, 2020 2019 (in thousands) Inventories: Work-in-process $ 414 $ 746 Finished goods 185 222 $ 599 $ 968 Prepaid expenses and other: Prepaid inventory and production costs $ 422 $ 174 Prepaid insurance 144 122 Prepaid software 18 24 Refundable tax — 61 Other 84 91 $ 668 $ 472 Property and equipment, net: Equipment, furniture and fixtures and leasehold improvements $ 4,265 $ 4,239 Acquired software 129 123 4,394 4,362 Less: Accumulated depreciation and amortization (4,273 ) (4,165 ) $ 121 $ 197 Accrued expenses and other: December 31, 2020 2019 (in thousands) Accrued wages and employee benefits $ 313 $ 296 Professional fees, legal and consulting 690 229 IC development and wafer purchases — 104 Warranty accrual 41 63 Interest payable 93 84 Corporate taxes 18 20 Other 145 359 $ 1,300 $ 1,155

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3: Fair Value of Financial Instruments The estimated fair values of financial instruments outstanding were (in thousands): December 31, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 5,889 $ — $ — $ 5,889 December 31, 2019 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,053 $ — $ — $ 6,053 Short-term investments 300 — — 300 $ 6,353 $ — $ — $ 6,353 The unrealized losses from available-for-sale securities as of December 31, 2020 and 2019 were not material. The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) as of December 31, 2020 and 2019 (in thousands): December 31, 2020 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,893 $ 3,893 $ — $ — December 31, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 4,574 $ 4,574 $ — $ — Corporate notes and commercial paper $ 300 $ — $ 300 $ — During the year ended December 31, 2020, $0.3 million of corporate notes and commercial paper matured and were transferred to Level 1. There were no transfers in or out of Level 1 and Level 2 securities during the year ended December 31, 2019.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 4: Income Taxes The income tax provision (benefit) consisted of the following (in thousands): Year Ended December 31, 2020 2019 Current portion: Federal $ — $ (182 ) Deferred portion: Federal — 182 $ — $ — Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities were (in thousands): Year Ended December 31, 2020 2019 Deferred tax assets: Federal and state loss carryforwards $ 3,031 $ 1,697 Reserves, accruals and other 239 156 Depreciation and amortization 1,284 1,629 Deferred stock-based compensation 2,698 2,613 Research and development credit carryforwards 6,613 6,707 Foreign tax and other credits - 61 Total deferred tax assets 13,865 12,863 Less: Valuation allowance (13,865 ) (12,802 ) Net deferred tax assets $ — $ 61 The $1.1 million increase in the valuation allowance during 2020 was primarily the result of an increase to the net operating loss carryforwards for the current year. The valuation allowance increased by $0.9 million during the year ended December 31, 2019. Utilization of the Company’s net operating losses (NOLs) and tax credit carryforwards is subject to a substantial annual limitation due to the ownership change limitations provided by the IRC and similar state provisions. Section 382 of the IRC (Section 382) imposes limitations on a corporation’s ability to utilize its NOL and tax credit carryforwards, if it experiences an “ownership change.” In general terms, an ownership change may result from transactions increasing the ownership percentage of certain stockholders in the stock of the corporation by more than 50% over a three-year period. In the event of an ownership change, utilization of the NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate. While a formal study has not been performed, the Company believes that a Section 382 ownership change occurred as a result of a financing effected in October 2018. The Company believes this Section 382 limitation will result in approximately 97% of the federal and state NOLs expiring before they can be utilized, and approximately 96% of the federal tax credit carryforwards expiring before they can be utilized. As of December 31, 2020, the Company had NOLs of approximately $205.2 million for federal income tax purposes and approximately $127.0 million for state income tax purposes. Only approximately $11.3 million of the federal NOLs and $9.5 million of the state NOLs are expected to be available before expiration due to the Section 382 limitation. These NOLs are available to reduce future taxable income and will expire at various times from 2025 through 2037, except federal NOLs from 2018 to 2020 which will never expire. The Company also had federal research and development tax credit carryforwards of approximately $8.7 million, which will begin expiring in 2020, and California research and development credits of approximately $8.4 million, which do not have an expiration date. A reconciliation of income taxes provided at the federal statutory rate (21%) to the actual income tax provision is as follows (in thousands): Year Ended December 31, 2020 2019 Income tax benefit computed at U.S. statutory rate $ (794 ) $ (542 ) Research and development credits (66 ) (170 ) Amortization of intangible assets (60 ) (60 ) Goodwill impairment — 17 Valuation allowance changes affecting tax provision 919 752 Other 1 3 Income tax provision $ — $ — The losses before income tax provision for the years ended December 31, 2020 and 2019 were solely attributable to US operations.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 5: Stock-Based Compensation Equity Compensation Plans Common Stock Equity Plans In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The Amended 2010 Plan was terminated in August 2019 and remains in effect as to outstanding equity awards granted prior to the date of expiration. As of December 31, 2019, no new awards may be made under the Amended 2010 Plan, and equity awards for approximately 172,000 shares were outstanding. In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and it replaced the Amended 2010 Plan. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares have been reserved for issuance. The 2019 Plan provides for annual option grants or other awards to the Company’s non-employee directors to acquire up to 2,000 shares and for a one-time grant of an option or other award to a non-employee director to acquire up to 6,000 shares upon his or her initial appointment or election to the board of directors. Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company. The Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.” The Company may also award shares to new employees outside the Plans, as material inducements to the acceptance of employment with the Company, as permitted under the Listing Rules of the Nasdaq Stock Market. These awards must be approved by the compensation committee of the board of directors, a majority of the independent directors or, below a specified share level, by an authorized executive officer. At December 31, 2020 and 2019, no such awards were outstanding. Stock-Based Compensation Expense The unamortized compensation cost, at December 31, 2020, was $0.2 million related to stock options and is expected to be recognized as expense over a weighted average period of approximately 1.4 years. The unamortized compensation cost, at December 31, 2020, was $0.3 million related to restricted stock units and is expected to be recognized as expense over a weighted average period of approximately 0.8 years. For the years ended December 31, 2020 and 2019, the fair value of options and awards vested was approximately $0.2 million and $0.3 million, respectively. Valuation Assumptions and Expense Information for Stock-based Compensation The fair value of the Company’s share-based payment awards for the years ended December 31, 2020, and 2019 was estimated on the grant dates using the Black-Scholes model with the following assumptions: Year Ended December 31, 2020 2019 Risk-free interest rate 1.6% - 2.5% 1.6% - 2.5% Volatility 128% - 138.5% 128% - 138.5% Expected life (years) 3.0 - 5.0 3.0 - 5.0 Dividend yield 0 % 0 % The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. The expected volatility was based on the historical volatility of the Company’s stock price over the expected term of the options. The expected term of options granted was derived from historical data based on employee exercises and post-vesting employment termination behavior. A dividend yield of zero is applied because the Company has never paid dividends and has no intention to pay dividends in the near future. Prior to January 1, 2019, the stock-based compensation expense recorded was adjusted based on estimated forfeiture rates. An annualized forfeiture rate was used as a best estimate of future forfeitures based on the Company’s historical forfeiture experience. The stock-based compensation expense was adjusted in later periods if the actual forfeiture rate is different from the estimate. Upon the adoption of ASU No. 2016-09 on January 1, 2019, the Company elected to change its accounting policy to account for forfeitures as they occur. Historically, estimated forfeitures were immaterial to the consolidated financial statements. Common Stock Options and Restricted Stock A summary of stock option and restricted stock unit (RSU) award activity under the Plans is presented below (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2019 200 17 $ 96.24 Additional shares authorized under the Plan 183 — — RSUs granted (120 ) — — RSUs cancelled and returned to the Plan 1 — — Options granted (145 ) 145 $ 2.64 Options cancelled and returned to the Plan 1 (1 ) $ 144.00 Plan termination (32 ) — $ — Balance as of December 31, 2019 88 161 $ 10.85 RSUs granted (9 ) — — RSUs cancelled and returned to the Plan 2 — — Options cancelled — (2 ) $ 4.00 Balance as of December 31, 2020 81 159 $ 10.82 A summary of RSU activity under the Plans is presented below (in thousands, except fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2019 14 $ 24.31 Granted 120 $ 3.79 Vested (30 ) $ 12.89 Cancelled (1 ) $ 25.13 Non-vested shares as of December 31, 2019 103 $ 3.75 Granted 9 $ 1.74 Vested (43 ) $ 3.72 Cancelled (4 ) $ 4.00 Non-vested shares as of December 31, 2020 65 $ 3.48 The total intrinsic value of outstanding RSUs was The following table summarizes significant ranges of outstanding and exercisable options at December 31, 2020 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $1.57 - $14.99 143 8.26 $ 2.62 68 $ 2.94 $ 25 $15.00 - $25.59 8 2.74 $ 15.00 8 $ 15.00 $ — $25.60 - $143.99 2 3.35 $ 41.81 2 $ 41.81 $ — $144.00 - $409.99 5 5.65 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 4.19 $ 430.64 1 $ 430.64 $ — $1.57 - $924.00 159 7.80 $ 10.82 84 $ 18.39 $ 25 There were no stock options exercised during the years ended December 31, 2020 or 2019. The intrinsic value of outstanding options at December 31, 2019 was $0.1 million.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Stockholders Equity Note [Abstract]
Stockholders' Equity	Note 6: Stockholders’ Equity In April 2020, the Company completed a registered direct offering of securities and sold 1,218,000 shares of common stock at a price of $1.56 per share to institutional investors. Net proceeds of the offering, after placement agent and other fees and expenses paid by the Company, were approximately $1.6 million. As a result of the offering, the exercise price of the 1,845,540 outstanding common stock purchase warrants that were issued in October 2018 was reduced from $6.00 per share to $2.40 per share. The Company accounted for the warrant exercise price adjustment in accordance with ASC Topic 260 and determined that the change in the exercise price resulted in a deemed dividend of $392,000 that increased the net loss attributable to common stockholders for the year ended December 31, 2020. Warrants At December 31, 2020, the Company had the following warrants outstanding (share amounts in thousands): Warrant Type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 1,846 $ 2.40 October 2023

Retirement Savings Plan

Retirement Savings Plan	12 Months Ended
	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
Retirement Savings Plan	Note 7: Retirement Savings Plan Effective January 1997, the Company adopted the MoSys 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section 401(k) of the Internal Revenue Code. Full-time and part-time employees who are at least 21 years of age are eligible to participate in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. No matching contributions were made by the Company during the years ended December 31, 2020 and 2019.

Business Segment, Concentration

Business Segment, Concentration of Credit Risk and Significant Customers	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Business Segment, Concentration of Credit Risk and Significant Customers	Note 8: Business Segment, Concentration of Credit Risk and Significant Customers The Company operates in one business segment and uses one measurement of profitability for its business. Revenue attributed to the United States and to all foreign countries is based on the geographical location of the customer. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. Cash, cash equivalents and investments are deposited with high credit-quality institutions. The Company recognized revenue from licensing of its technologies and shipment of ICs to customers in the following geographical locations (in thousands): Year Ended December 31, 2020 2019 North America $ 5,454 $ 7,585 Japan 675 1,734 Taiwan 459 345 Rest of world 207 422 Total net revenue $ 6,795 $ 10,086 Customers who accounted for at least 10% of total net revenues were: Year Ended December 31, 2020 2019 Customer A 37 % 30 % Customer B 22 % 14 % Customer C 10 % 17 % Customer D 10 % * Customer E * 13 % * Represents percentage less than 10%. Three customers accounted for 86% of net accounts receivable at December 31, 2020. Four customers accounted for 85% of net accounts receivable at December 31, 2019. All net long-lived assets (property and equipment) were held in the United States.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9: Commitments and Contingencies Leases Effective January 1, 2019, the Company adopted ASU No. 2016-02, as amended, using the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the “effective date method”). The Company identified only one lease to be accounted for under ASU No. 2016-02, and this was the operating lease for its corporate facility in San Jose, California, which was entered into in October 2017 and initially expired in October 2020. The right-to-use asset and corresponding liability for the facility lease were measured at the present value of the future minimum lease payments. The discount rate used to measure the lease asset and liability represents the interest rate on the Notes (8%). Lease expense is recognized on a straight line basis over the lease term. The Company had an option to extend the lease for an additional 20.5 month period, but, as the renewal was not reasonably certain, it had not included this renewal option in its accounting for the lease. On September 30, 2020, the Company and the lessor extended the lease for an additional 20.5 month term commencing November 1, 2020. The Company does not have an option to extend the lease term beyond the current extension The extension was accounted for as a lease modification. The Company assessed the lease classification of the facility lease at the modification date and determined that the facility lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term. The fair value of the right of use asset and corresponding lease obligation was determined to be $352,000 at the date of modification using a discount rate of 8%. Non-lease components are not included in the right-of-use asset and liability and are reflected as expense in the periods incurred. Future minimum payments under the facility lease at December 31, 2020 are listed in the table below (in thousands). Operating Year ended December 31, lease 2021 $ 206 2022 112 Total future lease payments 318 Less: imputed interest (14 ) Present value of lease liabilities $ 304 Year ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 220 $ 219 Non-cash activity: Recognition of additional right-of-use asset and liability upon lease modification $ 352 $ - Rent expense was approximately $212,000 for each of the years ended December 31, 2020 and 2019. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s consolidated financial statements for the years ended December 31, 2020 and 2019 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements. Product warranties The Company warrants its products to be free of defects generally for a period of three years. The Company estimates its warranty costs based on historical warranty claim experience and includes such costs in cost of net revenues. Warranty costs were not material for the years ended December 31, 2020 and 2019.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	Note 10: Notes Payable Convertible Notes In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the “Purchase Agreement”) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the “Notes”), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $170.00 of Note principal per share of common stock to $11.434 of Note principal per share of common stock. The conversion price is subject to adjustment upon certain events, such as stock splits, reverse stock splits, stock dividends and similar kinds of transactions, as set forth in the Purchase Agreement. Pursuant to a security agreement entered into by the Company, the Notes are secured by a security interest in all of the assets of the Company. Accrued interest is payable semi-annually in cash or in kind through the issuance of identical new Notes, or with a combination of the two, at the Company’s option. The Notes are noncallable and nonredeemable by the Company. The Notes are redeemable at the election of the holders if the Company experiences a fundamental change (as defined in the Notes), which generally would occur in the event (i) any person acquires beneficial ownership of shares of common stock of the Company entitling such person to exercise at least 40% of the total voting power of all of the shares of capital stock of the Company entitled to vote generally in elections of directors, (ii) an acquisition of the Company by another person through a merger or consolidation, or the sale, transfer or lease of all or substantially all of the Company’s assets, or (iii) the Company’s current directors cease to constitute a majority of the board of directors of the Company within a 12-month period, disregarding for this purpose any director who voluntarily resigns as a director or dies while serving as a director. Effective February 18, 2018, pursuant to one amendment to the Notes, the redemption price was reduced from 120% to 100% of the principal amount of the Note to be repurchased plus accrued and unpaid interest as of the redemption date. No Note holder shall be entitled to convert such holder’s Notes if effective upon the applicable conversion date (i) the holder would have beneficial ownership of more than 19.9% of the voting capital stock of the Company as determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, (with exceptions specified in the Purchase Agreement), or (ii) if the shares are being acquired or held with a purpose or effect of changing or influencing control of the Company, or in connection with or as a participant in any transaction having that purpose or effect, as determined in the sole discretion of the board of directors of the Company. There is no required sinking fund for the Notes. The Notes have not been registered for resale, and the holder(s) do not have registration rights. The Notes restrict the ability of the Company to incur any indebtedness for borrowed money, unless such indebtedness by its terms is expressly subordinated to the Notes in right of payment and to the security interest of the Note holder(s) in respect to the priority and enforcement of any security interest in property of the Company securing such new debt; provided that the Note holder(s) security interest and cash payment rights under the Notes shall be subordinate to a maximum of $5,000,000 of indebtedness for a secured accounts receivable line of credit facility provided to the Company by a bank or institutional lender; and, provided further, that in no event may the amount of indebtedness to which the security interest of the Note holder(s) is subordinated exceed the outstanding balance of accounts receivable less than 90 days old for which the Company has not recorded an allowance for doubtful accounts pledged under such credit facility. The Notes define an event of default generally as any failure by the Company to pay an amount owed under the Notes when due (subject to cure periods), a default with respect to other indebtedness of the Company resulting in acceleration of such indebtedness, the commencement of bankruptcy or insolvency proceedings, or the cessation of business. If an event of default occurs under the Notes, the holder(s) of a majority-in-interest of the outstanding principal amount of the Notes may declare the outstanding principal amount thereof to be immediately due and payable and pursue all available remedies, including taking possession of the assets of the Company and selling them to pay the amount of debt then due, plus expenses, in accordance with applicable laws and procedures. The Company incurred debt issuance costs of approximately $0.1 million, which were recorded as a debt discount and were amortized to interest expense over the repayment period for the original loan term using the effective interest rate method. As of December 31, 2018, the debt discount was fully amortized. In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from its public offering of securities effected in October 2018 to repay a portion of the Notes. Semi-annual interest payments have been made in each of February 2019, August 2019, February 2020 and August 2020, for approximately, $78,000, $109,000, $112,000 and $122,000, respectively, in-kind with the issue of additional notes (Interest Notes) to the Purchasers. The Interest Notes have terms identical to the Notes. At December 31, 2020, the Notes and Interest Notes could be converted into a maximum of 271,121 shares of common stock at $11.434 per share, excluding the effects of future payments of interest in-kind. PPP Note On May 7, 2020, the Company entered into a Promissory Note with Wells Fargo Bank, N.A. (the Lender) in an aggregate principal amount of $579,330 (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act. The term of the PPP Note is two years. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%, which shall be deferred for the first ten months of the term of the PPP Note. Monthly payments will be due and payable beginning in October 2021 and continue each month thereafter until maturity of the PPP Note. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company. The Company may apply to the Lender for forgiveness of the PPP Note, under the terms of the PPP. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part, but the Company believes it has used the proceeds in accordance with the PPP. If the PPP Note is not forgiven, principal payments will start in 2021.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Warrants Subsequent to December 31, 2020, the Company received a total of $2,478,461 of proceeds from the exercise of 1,032,692 warrants to purchase shares of common stock at a price of $2.40 per share. Financing In February 2021, the Company completed a registered direct offering and sold 1,487,601 shares of common stock at a price of $5.00 per share to institutional investors. Notes Under an agreement with the holder of the Notes, who was also a holder of warrants, in January and February 2021, the Company used $1,473,098 of the proceeds from the Note holder’s warrant exercises to repay a portion of the principal amount of the Notes. In March 2021, the Company repaid in full the remaining principal amount of the Notes.

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.
COVID-19	COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted. In March 2020, Santa Clara County in California, where the Company is based, issued a ”shelter-in-place” order (the Order) that was initially effective through April 7, 2020 and has now been extended. The Company has been complying with the Order and have minimized business activities at the San Jose headquarters facility (the only facility). The Company has implemented a teleworking policy for employees and contractors to reduce on-site activity at the facility. The Order impacted the Company’s ability to produce and ship IC products in the second half of March 2020, as certain vendors in the San Francisco Bay Area closed in accordance with the Order. In April 2020, the Company resumed shipments of IC products, as they are supporting shipment of components for critical infrastructure, as defined by the federal government; however, employees are generally restricted from visiting customer and vendor sites in compliance with the Order, and, in some cases, have limited ability to conduct certain product testing and development activities. The Company remains diligent in continuing to identify and manage risks to our business given the changing uncertainties related to COVID-19. The ultimate impact of the Covid-19 pandemic on the business and results of operations is uncertain and difficult to predict, and the Company is closely monitoring impacts, especially to customer programs and our supply chain. The Company expects that the impacts of the COVID-19 pandemic will have a negative impact on its revenues for 2021, although the Company is not in a position to quantify such impacts. In addition, the Company has and continues to experience longer lead times for certain components used to manufacture its IC products. While the Company believes that operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, they recognize that unpredictable events could create difficulties in the months ahead. The Company may not be able to address these difficulties in a timely manner, which could negatively impact its business, results of operations, financial condition and cash flows.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Material estimates may include assumptions made in determining reserves for uncollectible receivables, inventory write-downs, impairment of long-term assets, valuation allowance on deferred tax assets, accruals for potential liabilities and assumptions made in valuing equity instruments.
Cash Equivalents and Investments	Cash Equivalents and Investments The Company has invested its excess cash in money market accounts, certificates of deposit, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term and long-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income (loss). Realized gains and losses and declines in the value judged to be other-than-temporary are included in the other income, net line item in the consolidated statements of operations. The cost of securities sold is based on the specific identification method.
Fair Value Measurements	Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2—Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities include cash equivalents and available-for-sale securities, which consisted primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3—Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts receivable was $41,000 and zero as of December 31, 2020 and 2019, respectively.
Inventories	Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow-moving inventory items. The Company recorded inventory write-downs of $0.1 million for each of the years ended December 31, 2020 and 2019.
Property and Equipment	Property and Equipment Property and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in cost of sales and operating expenses in the consolidated statements of operations and comprehensive loss. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.
Valuation of Long-lived Assets	Valuation of Long-lived Assets The Company evaluates the recoverability of long-lived assets with finite lives whenever events or changes in circumstances occur that indicate that the carrying value of the asset or asset group may not be recoverable. Finite-lived intangible assets are being amortized on a straight-line basis over their estimated useful lives of three to seven years. An impairment charge is recognized as the difference between the net book value of such assets and the fair value of such assets at the date of measurement. The measurement of impairment requires management to estimate future cash flows and the fair value of long-lived assets.
Goodwill	Goodwill The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired. If the carrying value of the reporting unit’s goodwill exceeds its fair value, then the Company must record an impairment charge equal to the difference. The Company performed its annual test for goodwill impairment as of September 1, 2019, and, due to a decrease in the price per share of its common stock, the test results indicated the goodwill carrying value was greater than its implied fair value. Further, the Company concluded a triggering event had occurred due to the sustained decrease in the price per share of its common stock and related reduced market capitalization as of September 30, 2019 and performed an additional test for impairment of its goodwill asset resulting in further indication that the goodwill carrying value was still greater than its implied fair value. As a result of both of these tests, the Company recorded non-cash impairment charges totaling $0.4 million. As a result of these charges, the Company’s goodwill balance was reduced to zero at September 30, 2019.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Financial Accounting Standards Board ( Revenue from Contracts with Customers, As described below, the analysis of contracts under ASC 606 supports the recognition of revenue at a point in time, resulting in revenue recognition timing that is materially consistent with the Company’s historical practice of recognizing product revenue when title and risk of loss pass to the customer. The Company generates revenue primarily from sales of IC products and licensing of its intellectual property. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company's contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less. The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. As of December 31, 2020, contract liabilities were in a current position and included in deferred revenue. During the year ended December 31, 2020, the Company recognized revenue of $0.2 million that had been included in deferred revenue as of December 31, 2019. During the year ended December 31, 2019, the Company recognized revenue of $0.3 million that had been included in deferred revenue as of December 31, 2018. See Note 8 for disaggregation of revenue by geography. The Company does not have significant financing components, as payments from customers are typically due within 60 days of invoicing, and the Company has elected the practical expedient to net value financing components that are less than one year. Shipping and handling costs are generally incurred by the customer, and, therefore, are not recorded as revenue.
Cost of Net Revenue	Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. Advertising costs were not significant for the years ended December 31, 2020 and 2019.
Research and Development	Research and Development Engineering costs are recorded as research and development expense in the period incurred.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees. The Company accounts for such grants based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the vesting period. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.
Per Share Amounts	Per Share Amounts Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and purchases under the employee stock purchase plan, conversion of convertible debt and exercise of warrants. The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): December 31, 2020 2019 Options to purchase common stock 159 161 Unvested restricted common stock units 65 103 Convertible debt 271 254 Warrants 1,879 1,994 Total 2,374 2,512
Income Taxes	Income Taxes The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. The 2014 through 2018 tax years generally remain subject to examination by U.S. federal and state tax authorities, and the 2010 through 2019 tax years generally remain subject to examination by foreign tax authorities. At December 31, 2020, the Company did not have any material unrecognized tax benefits nor expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest related to unrecognized tax benefits as income tax expense and penalties related to unrecognized tax benefits as other income and expense. During the years ended December 31, 2020 and 2019, the Company did not recognize any interest or penalties related to unrecognized tax benefits.
Comprehensive Loss	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2020 and 2019, the Company’s comprehensive loss was the same as its net loss.

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): December 31, 2020 2019 Options to purchase common stock 159 161 Unvested restricted common stock units 65 103 Convertible debt 271 254 Warrants 1,879 1,994 Total 2,374 2,512

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	12 Months Ended
	Dec. 31, 2020
Consolidated Balance Sheets And Statements Of Operations Components Disclosure [Abstract]
Schedule of Inventories/Prepaid/PP&E	December 31, 2020 2019 (in thousands) Inventories: Work-in-process $ 414 $ 746 Finished goods 185 222 $ 599 $ 968 Prepaid expenses and other: Prepaid inventory and production costs $ 422 $ 174 Prepaid insurance 144 122 Prepaid software 18 24 Refundable tax — 61 Other 84 91 $ 668 $ 472 Property and equipment, net: Equipment, furniture and fixtures and leasehold improvements $ 4,265 $ 4,239 Acquired software 129 123 4,394 4,362 Less: Accumulated depreciation and amortization (4,273 ) (4,165 ) $ 121 $ 197
Schedule of accrued expenses and other	December 31, 2020 2019 (in thousands) Accrued wages and employee benefits $ 313 $ 296 Professional fees, legal and consulting 690 229 IC development and wafer purchases — 104 Warranty accrual 41 63 Interest payable 93 84 Corporate taxes 18 20 Other 145 359 $ 1,300 $ 1,155

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Values of Financial Instruments Outstanding	The estimated fair values of financial instruments outstanding were (in thousands): December 31, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 5,889 $ — $ — $ 5,889 December 31, 2019 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,053 $ — $ — $ 6,053 Short-term investments 300 — — 300 $ 6,353 $ — $ — $ 6,353
Schedule of Fair Value Hierarchy for Financial Assets (Cash Equivalents and Investments)	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) as of December 31, 2020 and 2019 (in thousands): December 31, 2020 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,893 $ 3,893 $ — $ — December 31, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 4,574 $ 4,574 $ — $ — Corporate notes and commercial paper $ 300 $ — $ 300 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Income Tax Provision (Benefit)	The income tax provision (benefit) consisted of the following (in thousands): Year Ended December 31, 2020 2019 Current portion: Federal $ — $ (182 ) Deferred portion: Federal — 182 $ — $ —
Significant Components of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities were (in thousands): Year Ended December 31, 2020 2019 Deferred tax assets: Federal and state loss carryforwards $ 3,031 $ 1,697 Reserves, accruals and other 239 156 Depreciation and amortization 1,284 1,629 Deferred stock-based compensation 2,698 2,613 Research and development credit carryforwards 6,613 6,707 Foreign tax and other credits - 61 Total deferred tax assets 13,865 12,863 Less: Valuation allowance (13,865 ) (12,802 ) Net deferred tax assets $ — $ 61
Reconciliation of Income taxes Provided at Federal Statutory Rate to Actual Income Tax Provision (Benefit)	A reconciliation of income taxes provided at the federal statutory rate (21%) to the actual income tax provision is as follows (in thousands): Year Ended December 31, 2020 2019 Income tax benefit computed at U.S. statutory rate $ (794 ) $ (542 ) Research and development credits (66 ) (170 ) Amortization of intangible assets (60 ) (60 ) Goodwill impairment — 17 Valuation allowance changes affecting tax provision 919 752 Other 1 3 Income tax provision $ — $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Assumptions used in Estimation of Fair Value of the Share-based Payment Awards on the Grant Date	Year Ended December 31, 2020 2019 Risk-free interest rate 1.6% - 2.5% 1.6% - 2.5% Volatility 128% - 138.5% 128% - 138.5% Expected life (years) 3.0 - 5.0 3.0 - 5.0 Dividend yield 0 % 0 %
Summary of Option and RSU Activity under Amended and Restated 2000 Stock Option and Equity Incentive Plan and Amended and Restated 2010 Equity Incentive Plan	A summary of stock option and restricted stock unit (RSU) award activity under the Plans is presented below (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2019 200 17 $ 96.24 Additional shares authorized under the Plan 183 — — RSUs granted (120 ) — — RSUs cancelled and returned to the Plan 1 — — Options granted (145 ) 145 $ 2.64 Options cancelled and returned to the Plan 1 (1 ) $ 144.00 Plan termination (32 ) — $ — Balance as of December 31, 2019 88 161 $ 10.85 RSUs granted (9 ) — — RSUs cancelled and returned to the Plan 2 — — Options cancelled — (2 ) $ 4.00 Balance as of December 31, 2020 81 159 $ 10.82
Summary of RSU Activity under the Plans	A summary of RSU activity under the Plans is presented below (in thousands, except fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2019 14 $ 24.31 Granted 120 $ 3.79 Vested (30 ) $ 12.89 Cancelled (1 ) $ 25.13 Non-vested shares as of December 31, 2019 103 $ 3.75 Granted 9 $ 1.74 Vested (43 ) $ 3.72 Cancelled (4 ) $ 4.00 Non-vested shares as of December 31, 2020 65 $ 3.48
Summary of Significant Ranges of Outstanding and Exercisable Options	The following table summarizes significant ranges of outstanding and exercisable options at December 31, 2020 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $1.57 - $14.99 143 8.26 $ 2.62 68 $ 2.94 $ 25 $15.00 - $25.59 8 2.74 $ 15.00 8 $ 15.00 $ — $25.60 - $143.99 2 3.35 $ 41.81 2 $ 41.81 $ — $144.00 - $409.99 5 5.65 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 4.19 $ 430.64 1 $ 430.64 $ — $1.57 - $924.00 159 7.80 $ 10.82 84 $ 18.39 $ 25

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders Equity Note [Abstract]
Schedule of Warrants Outstanding	At December 31, 2020, the Company had the following warrants outstanding (share amounts in thousands): Warrant Type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 1,846 $ 2.40 October 2023

Business Segment, Concentrati_2

Business Segment, Concentration of Credit Risk and Significant Customers (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location	The Company recognized revenue from licensing of its technologies and shipment of ICs to customers in the following geographical locations (in thousands): Year Ended December 31, 2020 2019 North America $ 5,454 $ 7,585 Japan 675 1,734 Taiwan 459 345 Rest of world 207 422 Total net revenue $ 6,795 $ 10,086
Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue	Customers who accounted for at least 10% of total net revenues were: Year Ended December 31, 2020 2019 Customer A 37 % 30 % Customer B 22 % 14 % Customer C 10 % 17 % Customer D 10 % * Customer E * 13 % * Represents percentage less than 10%.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments under Operating Lease Facility	Future minimum payments under the facility lease at December 31, 2020 are listed in the table below (in thousands). Operating Year ended December 31, lease 2021 $ 206 2022 112 Total future lease payments 318 Less: imputed interest (14 ) Present value of lease liabilities $ 304
Schedule of Supplemental Cash Flow Information Related to Operating lease	Year ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 220 $ 219 Non-cash activity: Recognition of additional right-of-use asset and liability upon lease modification $ 352 $ -

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Maximum specific allowance as percentage of invoice value for problematic customer balances		100.00%
Allowance for doubtful accounts receivable		$ 41,000	$ 0
Inventory reserves		$ 100	100
Impairment of goodwill	$ 400		420
Goodwill balance	$ 0
Payment terms		The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less
Deferred revenue, revenue recognized		$ 200	$ 300
Period payments due from customers		60 days
Revenue, practical expedient, financing component		true
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment		3 years
Estimated useful lives of long-lived assets		3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment		5 years
Estimated useful lives of long-lived assets		7 years

The Company and Summary of Si_5

The Company and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,374	2,512
Options to Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	159	161
RSU's
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	65	103
Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	271	254
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,879	1,994

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail - Schedule of Inventories/Prepaid/PP&E (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventories:
Work-in-process	$ 414	$ 746
Finished goods	185	222
Total	599	968
Prepaid expenses and other:
Prepaid inventory and production costs	422	174
Prepaid insurance	144	122
Prepaid software	18	24
Refundable tax		61
Other	84	91
Total	668	472
Property and equipment, net:
Property and equipment, gross	4,394	4,362
Less: Accumulated depreciation and amortization	(4,273)	(4,165)
Property and equipment, net	121	197
Equipment, furniture and fixtures and leasehold improvements
Property and equipment, net:
Property and equipment, gross	4,265	4,239
Acquired software
Property and equipment, net:
Property and equipment, gross	$ 129	$ 123

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued expenses and other:
Accrued wages and employee benefits	$ 313	$ 296
Professional fees, legal and consulting	690	229
IC development and wafer purchases		104
Warranty accrual	41	63
Interest payable	93	84
Corporate taxes	18	20
Other	145	359
Total	$ 1,300	$ 1,155

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Estimated Fair Values of Financial Instruments Outstanding (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Cost		$ 6,353
Unrealized Gains		0
Unrealized Losses		0
Fair Value		6,353
Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Cost	$ 5,889	6,053
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	$ 5,889	6,053
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Cost		300
Unrealized Gains		0
Unrealized Losses		0
Fair Value		$ 300

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy for Financial Assets (Cash Equivalents and Investments) (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Money market funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value	$ 3,893	$ 4,574
Money market funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value	$ 3,893	4,574
Corporate notes and commercial paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value		300
Corporate notes and commercial paper | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value		$ 300

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer of assets between Level 1 to Level 2		$ 0
Transfer of assets between Level 2 to Level 1		0
Transfer of liabilities between Level 1 to Level 2		0
Transfer of liabilities between Level 2 to Level 1		$ 0
Level 1 | Corporate notes and commercial paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities matured	$ 300,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Benefit) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Current portion:
Federal	$ (182)
Deferred portion:
Federal	182
Income tax provision	$ 0

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Federal and state loss carryforwards	$ 3,031	$ 1,697
Reserves, accruals and other	239	156
Depreciation and amortization	1,284	1,629
Deferred stock-based compensation	2,698	2,613
Research and development credit carryforwards	6,613	6,707
Foreign tax and other credits		61
Total deferred tax assets	13,865	12,863
Less: Valuation allowance	$ (13,865)	(12,802)
Net deferred tax assets		$ 61

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Increase (decrease) in valuation allowance during the year	$ 1.1	$ 0.9
Percentage of limitation on federal and state net operating loss carryforwards	97.00%
Percentage of limitation on federal tax credit carryforwards	96.00%
Federal
Income Taxes [Line Items]
Net operating loss carryforwards, amount	$ 205.2
Net operating loss carryforwards available before expiration	11.3
Federal | Research and development
Income Taxes [Line Items]
Tax credit carryforwards with expiration	8.7
State
Income Taxes [Line Items]
Net operating loss carryforwards, amount	127
Net operating loss carryforwards available before expiration	9.5
State | Research and development
Income Taxes [Line Items]
Tax credit carryforwards without expiration	$ 8.4
Earliest Tax Year
Income Taxes [Line Items]
Net operating loss carryforwards, expiration year	2025
Latest Tax Year
Income Taxes [Line Items]
Net operating loss carryforwards, expiration year	2037

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income taxes Provided at Federal Statutory Rate to Actual Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income tax benefit computed at U.S. statutory rate	$ (794)	$ (542)
Research and development credits	(66)	(170)
Amortization of intangible assets	(60)	(60)
Goodwill impairment		17
Valuation allowance changes affecting tax provision	919	752
Other	$ 1	3
Income tax provision		$ 0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Aggregate Intrinsic Value		$ 100,000
New Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding awards	0	0
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unamortized compensation cost, net of expected forfeitures	$ 200,000
Weighted average expected period over which the expense is to be recognized	1 year 4 months 24 days
Fair value of vested options and awards	$ 200,000	$ 300,000
Dividend yield (as a percent)	0.00%	0.00%
Stock options exercised	0	0
RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unamortized compensation cost, net of expected forfeitures	$ 300,000
Weighted average expected period over which the expense is to be recognized	9 months 18 days
Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted (in shares)		0
Outstanding awards		172,000
Equity Incentive Plan 2010 | RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of the restricted stock units outstanding	$ 200,000	$ 200,000
Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance	182,500
Stock Incentive Plan 2019 | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum annual option grants or other awards to the entity's non-employee directors (in shares)	2,000
Maximum one-time grant of an option or other awards to the entity's non employee directors (in shares)	$ 6,000
Minimum percentage of voting rights required for applicability of a specific expiration term	10.00%
Maximum expiration term of options granted	5 years
Term of plan	10 years
Stock Incentive Plan 2019 | Options | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options	3 years
Stock Incentive Plan 2019 | Options | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options	4 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of the Share-based Payment Awards on the Grant Date (Detail) - Options	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	1.60%	1.60%
Risk-free interest rate, maximum	2.50%	2.50%
Volatility, minimum	128.00%	128.00%
Volatility, maximum	138.50%	138.50%
Dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	3 years	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	5 years	5 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Option and RSU Activity (Detail) - Equity Incentive Plan 2019 - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Shares Available for Grant
Balance at the beginning of the year (in shares)	88,000	200,000
Options granted (in shares)		(145,000)
Options cancelled and returned to Plan (in shares)		1,000
Plan termination (in shares)		(32,000)
Balance at the end of the period (in shares)	81,000	88,000
Number of Shares
Balance at the beginning of the year (in shares)	161,000	17,000
Options granted (in shares)		145,000
Options cancelled and returned to Plan (in shares)	(2,000)	(1,000)
Balance at the end of the period (in shares)	159,000	161,000
Weighted Average Exercise Prices
Weighted-average exercise price (in dollars per share)	$ 10.85	$ 96.24
Options granted (in dollars per share)		2.64
Options cancelled and returned to Plan (in dollars per share)	4	144
Weighted-average exercise price (in dollars per share)	$ 10.82	$ 10.85
Options
Shares Available for Grant
Additional shares authorized under the Plan		183,000
RSU's
Shares Available for Grant
RSUs granted (in shares)	(9,000)	(120,000)
RSUs cancelled and returned to Plan (in shares)	2,000	1,000
Number of Shares
RSUs cancelled and returned to Plan (in shares)	2,000	1,000
Weighted Average Exercise Prices
RSUs granted (in dollars per share)	$ 1.74	$ 3.79
RSUs cancelled and returned to Plan (in dollars per shares)	$ 4	$ 25.13

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity Under Plans (Detail) - Equity Incentive Plan 2019 - RSU's - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Non-vested shares at the beginning of the year	103,000	14,000
Granted (in shares)	9,000	120,000
Vested (in shares)	(43,000)	(30,000)
Cancelled (in shares)	(4,000)	(1,000)
Non-vested shares at the end of the period	65,000	103,000
Weighted Average Grant-Date Fair Value
Weighted average grant date fair value	$ 3.75	$ 24.31
Granted (in dollars per share)	1.74	3.79
Vested (in dollars per share)	3.72	12.89
Cancelled (in dollars per shares)	4	25.13
Weighted average grant date fair value	$ 3.48	$ 3.75

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Significant Ranges of Outstanding and Exercisable Options (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Aggregate Intrinsic Value		$ 100
Options | $1.57 - $14.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 1.57
Upper range limit (in dollars per share)	$ 14.99
Number Outstanding (in shares)	143
Weighted Average Remaining Contractual Life	8 years 3 months 3 days
Weighted Average Exercise Price (in dollars per share)	$ 2.62
Number Exercisable (in shares) | shares	68
Weighted Average Exercise Price (in dollars per share)	$ 2.94
Options Outstanding, Aggregate Intrinsic Value	$ 25
Options | $15.00 - $25.59
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 15
Upper range limit (in dollars per share)	$ 25.59
Number Outstanding (in shares)	8
Weighted Average Remaining Contractual Life	2 years 8 months 26 days
Weighted Average Exercise Price (in dollars per share)	$ 15
Number Exercisable (in shares) | shares	8
Weighted Average Exercise Price (in dollars per share)	$ 15
Options | $25.60 - $143.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	25.60
Upper range limit (in dollars per share)	$ 143.99
Number Outstanding (in shares)	2
Weighted Average Remaining Contractual Life	3 years 4 months 6 days
Weighted Average Exercise Price (in dollars per share)	$ 41.81
Number Exercisable (in shares) | shares	2
Weighted Average Exercise Price (in dollars per share)	$ 41.81
Options | $144.00 - $409.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	144
Upper range limit (in dollars per share)	$ 409.99
Number Outstanding (in shares)	5
Weighted Average Remaining Contractual Life	5 years 7 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 144
Number Exercisable (in shares) | shares	5
Weighted Average Exercise Price (in dollars per share)	$ 144
Options | $410.00 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	410
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares)	1
Weighted Average Remaining Contractual Life	4 years 2 months 8 days
Weighted Average Exercise Price (in dollars per share)	$ 430.64
Number Exercisable (in shares) | shares	1
Weighted Average Exercise Price (in dollars per share)	$ 430.64
Options | $1.57 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	1.57
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares)	159
Weighted Average Remaining Contractual Life	7 years 9 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 10.82
Number Exercisable (in shares) | shares	84
Weighted Average Exercise Price (in dollars per share)	$ 18.39
Options Outstanding, Aggregate Intrinsic Value	$ 25

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)	Apr. 21, 2020USD ($)$ / sharesshares	Oct. 31, 2018$ / sharesshares	Dec. 31, 2020USD ($)
Stockholders Equity [Line Items]
Number of common stock sold | shares	1,218,000
Sale of stock, price per share | $ / shares	$ 1.56
Net proceeds of the offering | $	$ 1,600,000
Units offered during the period | shares		1,845,540
Exercise price of warrants | $ / shares	$ 2.40	$ 6
Deemed dividend for warrant exercise price adjustment | $			$ 392,000
Expected warrant life			3 years 6 months
Risk Free Interest Rate
Stockholders Equity [Line Items]
Warrants and rights outstanding, measurement input			1.6
Dividents
Stockholders Equity [Line Items]
Warrants and rights outstanding, measurement input			0
Expected Volatility
Stockholders Equity [Line Items]
Warrants and rights outstanding, measurement input			128

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - $ / shares shares in Thousands	Dec. 31, 2020	Apr. 21, 2020	Oct. 31, 2018
Class Of Warrant Or Right [Line Items]
Exercise Price		$ 2.40	$ 6
Common Stock Warrant One
Class Of Warrant Or Right [Line Items]
Number of Shares	33
Exercise Price	$ 47
Expiration	Jan. 31, 2023
Common Stock Warrant Two
Class Of Warrant Or Right [Line Items]
Number of Shares	1,846
Exercise Price	$ 2.40
Expiration	Oct. 31, 2023

Retirement Savings Plan - Addit

Retirement Savings Plan - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Minimum age for eligibility to participate in the Savings Plan	21 years
Maximum contribution by the participants (as a percent)	15.00%
Matching contribution by the Company	$ 0	$ 0

Business Segment, Concentrati_3

Business Segment, Concentration of Credit Risk and Significant Customers - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2020SegmentCustomer	Dec. 31, 2019Customer
Business Segments
Number of business segments | Segment	1
Number of measurements of profitability	1
Accounts receivable | Major customers | Credit concentration
Business Segments
Percentage of concentration risk	86.00%	85.00%
Number of customers | Customer	3	4

Business Segment, Concentrati_4

Business Segment, Concentration of Credit Risk and Significant Customers - Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Business Segments
Total net revenue	$ 6,795	$ 10,086
North America [Member]
Business Segments
Total net revenue	5,454	7,585
Japan [Member]
Business Segments
Total net revenue	675	1,734
Taiwan [Member]
Business Segments
Total net revenue	459	345
Rest of world [Member]
Business Segments
Total net revenue	$ 207	$ 422

Business Segment, Concentrati_5

Business Segment, Concentration of Credit Risk and Significant Customers - Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue (Detail) - Net Revenues - Customer Concentration	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Customer A
Significant Customers
Percentage of concentration risk	37.00%	30.00%
Customer B
Significant Customers
Percentage of concentration risk	22.00%	14.00%
Customer C
Significant Customers
Percentage of concentration risk	10.00%	17.00%
Customer D
Significant Customers
Percentage of concentration risk	10.00%
Customer E
Significant Customers
Percentage of concentration risk		13.00%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2020USD ($)Lease	Dec. 31, 2019USD ($)
Commitments And Contingencies Disclosure [Abstract]
Number of operating leases outstanding | Lease		1
Operating lease beginning period		2017-10
Operating lease expiration period		2020-10
Lessee, operating lease, discount rate		8.00%
Operating lease, option to extend		true
Available operating lease extension period		20 months 15 days
Operating lease, option to extend	the lessor extended the lease for an additional 20.5 month term commencing November 1, 2020. The Company does not have an option to extend the lease term beyond the current extension	option to extend the lease for an additional 20.5 month period
Operating lease extended term	20 months 15 days
Extended lease term starting date	Nov. 1, 2020
Fair value of right of use asset		$ 352,000,000
Fair value of operating lease liabilities		$ 352,000,000
Operating lease, discount rate		8.00%
Rent expenses		$ 212,000	$ 212,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Payments under Facility Operating Lease (Details) $ in Thousands	Dec. 31, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
2021	$ 206
2022	112
Total future lease payments	318
Less: imputed interest	(14)
Present value of lease liabilities	$ 304

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Operating lease (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for lease	$ 220	$ 219
Non-cash activity:
Recognition of additional right-of-use asset and liability upon lease modification	$ 352

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)	May 07, 2020	Feb. 18, 2018	Feb. 17, 2018	Aug. 31, 2020	Feb. 29, 2020	Aug. 31, 2019	Feb. 28, 2019	Oct. 31, 2018	Mar. 31, 2016	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Interest expense										$ 243,000	$ 220,000
Senior Secured Convertible Notes due August 15, 2018
Debt Instrument [Line Items]
Stated interest rate								8.00%	10.00%
Principal amount									$ 8,000,000
Redemption purchase price		100.00%	120.00%
Minimum ownership percentage triggering event for redemption of notes									40.00%
Maximum amount of indebtedness subordinated by security interest and cash payment rights under debt instruments									$ 5,000,000
Payment on principle amount of note								$ 7,400,000
Senior Secured Convertible Notes due August 15, 2018 | Contractual obligations and other termination costs
Debt Instrument [Line Items]
Debt issuance costs									$ 100,000
Senior Secured Convertible Notes due August 15, 2018 | Minimum
Debt Instrument [Line Items]
Percentage of beneficial ownership if effective upon conversion date of debt instrument									19.90%
Senior Secured Convertible Notes due August 15, 2018 | Maximum
Debt Instrument [Line Items]
Period for outstanding balance of accounts receivable has not recorded an allowance for doubtful accounts									90 days
Senior Secured Convertible Notes due August 15, 2023
Debt Instrument [Line Items]
Conversion price								$ 11.434	$ 170
Interest Note
Debt Instrument [Line Items]
Conversion price										$ 11.434
Number of shares issuable if notes converted to shares of common stock										271,121
Semi-annual interest payments				$ 122,000	$ 112,000	$ 109,000	$ 78,000
Promissory Note | PPP Note
Debt Instrument [Line Items]
Stated interest rate	1.00%
Principal amount	$ 579,330,000
Debt instrument term	2 years
Monthly payment beginning date	Oct. 31, 2021

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	Apr. 21, 2020	Feb. 28, 2021	Feb. 28, 2021	Mar. 18, 2021	Dec. 31, 2020	Oct. 31, 2018
Subsequent Event
Proceeds from warrant exercise					$ 2,000
Exercise price of warrants	$ 2.40					$ 6
Net proceeds of the offering	$ 1,600,000
Number of common stock sold	1,218,000
Sale of stock, price per share	$ 1.56
Subsequent Events
Subsequent Event
Proceeds from warrant exercise				$ 2,478,461
Warrant to purchase of common stock				1,032,692
Exercise price of warrants				$ 2.40
Net proceeds of the offering		$ 6,800,000
Number of common stock sold		1,487,601
Sale of stock, price per share		$ 5	$ 5
Subsequent Events | Notes
Subsequent Event
Proceeds from warrant exercise			$ 1,473,098